Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAY 2666605

X
Drug Profile

BAY 2666605

Alternative Names: BAY-2666605; SLFN12 ci

Latest Information Update: 29 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein-protein interaction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours

Most Recent Events

  • 08 Dec 2023 Bayer terminates a phase-I clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO, Liquid) due to high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit (NCT04809805)
  • 08 Dec 2023 Bayer terminates a phase-I clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet), due to high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit (NCT04809805)
  • 08 Dec 2023 Bayer terminates a phase I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO, Liquid) due to high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit (NCT04809805)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top